title: A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease.
authors.affiliation: Centre de référence des maladies neurogénétiques, Centre Hospitalier Universitaire, Angers, France.
authors.forename: Adriana
authors.initials: A
authors.lastname: Prundean
authors.forename: Katia
authors.initials: K
authors.lastname: Youssov
authors.forename: Sandrine
authors.initials: S
authors.lastname: Humbert
authors.forename: Dominique
authors.initials: D
authors.lastname: Bonneau
authors.forename: Christophe
authors.initials: C
authors.lastname: Verny
mesh_terms: D000293:Adolescent; D000328:Adult; D003543:Cysteamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004361:Drug Tolerance; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003543:Cysteamine
keywords: Huntington's disease; cysteamine; tolerability